Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$30.08 USD
-0.74 (-2.40%)
Updated May 15, 2024 04:00 PM ET
After-Market: $30.06 -0.02 (-0.07%) 6:10 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 141 - 160 ( 718 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Flexion Acquisition Adds ZILRETTA to Neural Pain Portfolio; Q3 Prelim Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Imitation is the Highest Form of Flattery: Pacira Defends EXPAREL from Generics
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL: Published Study Data Supports ~$100M Pediatric Market Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August 2021 Net Product Revenues; EXPAREL Growth Continues
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July 2021 Net Product Revenues; Highlights from Wedbush Fireside Chat
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2: EXPAREL Growth Outlook Keeps Long-Term Thesis In-Tact
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2Q21: Recent Weakness Likely Overplays Competitive or COVID Headwinds; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Preannounced 2Q Solid Exparel Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 Preliminary EXPAREL Sales Beat Par for the Course as Growth Continues
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L